RBC Capital analyst Craig Wong-Pan upgraded ResMed (RMD) to Outperform from Sector Perform with a price target of $294, up from $255. The firm expects the company to report solid fiscal 2025 results with a positive outlook for fiscal 2026. In addition, the stock’s valuation is “undemanding” while ResMed “offers a safe haven from tariffs,” the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- Morgan Stanley sees ‘modest’ earnings impact to ResMed from Apnimed
- Apnimed data brings competitive threat to ResMed, says RBC Capital
- Resmed’s Growth Potential Highlighted by Promising Trial Results and Future Opportunities
- Buy Rating for Resmed: Positive Phase 3 Trial Results and Market Conditions Boost AD109’s Appeal
- GOOGL, RMD: TipRanks’ New AI Analyst Tool Reveals 2 Stocks for Potential Growth